19-Jan-2021 - ViGeneron GmbH

Start-up ViGeneron announces research collaboration with Daiichi Sankyo

Evaluate vgAAV for novel ophthalmic gene therapy

ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction of target cells via intravitreal injection that allows efficient lateral spreading and minimizes the risk of collateral damage caused by conventional subretinal injection.

“There is significant unmet medical need for a sustained therapy to treat eye diseases. ViGeneron’s innovative gene therapy expertise combined with Daiichi Sankyo’s ophthalmic knowledge creates the potential to develop a sustained novel gene therapy to overcome the current limitations in treating this highly prevalent ophthalmic disease,” commented Dr. Caroline Man Xu, Co-founder and CEO of ViGeneron. “We look forward to working with Daiichi Sankyo to drive cutting-edge innovative science and to create an effective treatment for patients.”

Under the agreement, Daiichi Sankyo and ViGeneron will jointly conduct the first stage research and Daiichi Sankyo will have the option to negotiate a follow-on collaboration agreement for an undisclosed therapeutic target in the highly prevalent eye disease. Financial terms of the collaboration are not disclosed.

Facts, background information, dossiers
More about ViGeneron
  • News

    ViGeneron and Biogen collaborate

    ViGeneron GmbH announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered A ... more

    ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

    ViGeneron GmbH announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy ... more

  • Companies

    ViGeneron GmbH

    ViGeneron is a next generation gene therapy company dedicated to develop the innovative medicines of the future. Our team seeks to solve the major limitations of current gene therapy approaches. ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. more

More about Daiichi Sankyo